Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence
Neuropsychiatric Disease and Treatment · 2023-12 · Volume 19 · 2639-2655
DOI: 10.2147/ndt.s374694 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Neuropsychiatric Disease and Treatment, 2023-12. Verfasst von Tuan Vu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
- Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.
- Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Neurology, Concord Hospital, University of Sydney, Sydney, NSW, Australia.
- Department of Neurology, The University of North Carolina, Chapel Hill, NC, USA.
Zitieren
APA
Vu, T., Wiendl, H., Katsuno, M., Reddel, S. W., & Howard, J. F. (2023). Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence. Neuropsychiatric Disease and Treatment, Volume 19, 2639-2655. https://doi.org/10.2147/ndt.s374694
Vancouver
Vu T, Wiendl H, Katsuno M, Reddel SW, Howard JF. Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence. Neuropsychiatric Disease and Treatment. 2023;Volume 19:2639-2655. doi:10.2147/ndt.s374694
BibTeX
@article{Vu2023,
author = {Vu, Tuan and Wiendl, Heinz and Katsuno, Masahisa and Reddel, Stephen W and Howard, James F},
title = {Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence},
journal = {Neuropsychiatric Disease and Treatment},
year = {2023},
volume = {Volume 19},
pages = {2639--2655},
doi = {10.2147/ndt.s374694}
}
EUVIMED